Neurocrine Biosciences (FRA:NB3) Moat Score: 6/10 (As of Jul. 08, 2026)


FRA:NB3 Neurocrine Biosciences Inc FRA:NB3
94 GF Score
Price €153.55
GF Value €163.30
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Neurocrine Biosciences Moat Score?

Neurocrine Biosciences FRA:NB3 +0.23% 94 Moat Score is 6 as of Jul. 08, 2026. GuruFocus rates FRA:NB3 with a GF Score™ of 94/100 and a GF Value™ of €163.30 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Neurocrine Biosciences ranks better than 97.09% on this metric.

Neurocrine Biosciences has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Neurocrine Biosciences has Narrow Moat: Neurocrine Biosciences Inc has a strong narrow moat due to its valuable intellectual property and patents in the biotech sector. The company benefits from significant R&D capabilities and regulatory barriers in drug development. However, its market share and brand strength are not dominant enough to warrant a wide moat classification.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Neurocrine Biosciences might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Neurocrine Biosciences  (FRA:NB3) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Neurocrine Biosciences Moat Score Related Terms

FRA:NB3 vs VTRS, ELAN, UTHR: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurocrine Biosciences Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Moat Score distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's Moat Score falls into.


FRA:NB3
94GF Score
Neurocrine Biosciences Inc FRA:NB3
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Neurocrine Biosciences (FRA:NB3) has a Moat Score of 6 as of Jul. 08, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Neurocrine Biosciences ranks #30 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Neurocrine Biosciences' Moat Score too high?
Neurocrine Biosciences' current Moat Score is 6. Based on the distribution chart, Neurocrine Biosciences ranks #30 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Neurocrine Biosciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Moat Score compare to VTRS and ELAN?
According to the Drug Manufacturers industry distribution chart, Neurocrine Biosciences ranks #30 out of 1031 companies for Moat Score. This places Neurocrine Biosciences in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Neurocrine Biosciences's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (FRA:NB3) is currently considered Fairly Valued. The stock's GF Value™ is €163.30, compared to a current price of €153.55 — trading 6% below its estimated fair value. The current Moat Score is 6. Neurocrine Biosciences' overall GF Score™ is 94/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Neurocrine Biosciences (FRA:NB3), the current Moat Score is 6 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neurocrine Biosciences (FRA:NB3) Overvalued in 2026?

Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued. The current stock price of €153.55 is trading 6% below its estimated GF Value™ of €163.30. GuruFocus considers Neurocrine Biosciences to be Fairly Valued.

Key valuation signals for FRA:NB3:

  • Moat Score: 6
  • GF Value™: €163.30 vs. price of €153.55 (6% below fair value)
  • GF Score™: 94/100 with 6 warning signs

No single metric tells the full story. See the FRA:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neurocrine Biosciences Business Description

Address 6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
94GF Score

Get the complete analysis for FRA:NB3

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€153.55
Price
€163.30
GF Value